Unlock stock picks and a broker-level newsfeed that powers Wall Street.
31.12
-1.00
(-3.11%)
At close: March 28 at 4:00:01 PM EDT
31.20
+0.08
+(0.26%)
After hours: March 28 at 7:59:52 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 20 | 19 |
| Avg. Estimate | -3.14 | -3.08 | -10.16 | -7.77 |
| Low Estimate | -3.64 | -3.57 | -11.27 | -9.59 |
| High Estimate | -2.9 | -2.87 | -8.28 | -2.06 |
| Year Ago EPS | -3.07 | -3.33 | -9.28 | -10.16 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 25 | 23 |
| Avg. Estimate | 130.35M | 114.37M | 2.18B | 2.67B |
| Low Estimate | 83M | 39M | 1.51B | 1.87B |
| High Estimate | 183M | 172M | 2.88B | 5.38B |
| Year Ago Sales | 167M | 241M | 3.24B | 2.18B |
| Sales Growth (year/est) | -21.95% | -52.54% | -32.62% | 22.58% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -3.57 | -3.35 | -1.93 | -2.76 |
| EPS Actual | -3.07 | -3.33 | 0.03 | -2.91 |
| Difference | 0.5 | 0.02 | 1.96 | -0.15 |
| Surprise % | 14.06% | 0.65% | 101.55% | -5.44% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -3.14 | -3.08 | -10.16 | -7.77 |
| 7 Days Ago | -3.14 | -3.07 | -10.25 | -7.66 |
| 30 Days Ago | -3.08 | -3.05 | -10.07 | -7.4 |
| 60 Days Ago | -2.93 | -2.98 | -9.03 | -7.04 |
| 90 Days Ago | -3.13 | -3.16 | -8.93 | -6.98 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | 1 | 1 | -- | 2 |
| Down Last 30 Days | 1 | 1 | 2 | 5 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| MRNA | 0.03% | 7.24% | -10.16% | 25.70% |
| S&P 500 | 16.20% | 6.69% | 10.00% | 14.33% |
Top Analysts Yahoo Finance’s Top Analysts section provides an objective scorecard to evaluate the accuracy of Wall Street analyst ratings and price targets.
Learn More
Yahoo Finance’s Top Analysts section provides an objective scorecard to evaluate the accuracy of Wall Street analyst ratings and price targets.
Learn MoreAnalyst | Overall Score | Direction Score | Price Score | Latest Rating | Price Target | Date |
|---|---|---|---|---|---|---|
| Goldman Sachs | 69 | 48 | 98 | Neutral | 51 | 2025-01-30 |
| HSBC | 63 | 42 | 99 | Buy | 58 | 2024-11-19 |
| Argus Research | 62 | 50 | 92 | Hold | - | 2024-12-18 |
| Barclays | 61 | 33 | 97 | Equal-Weight | 45 | 2025-02-19 |
| Oppenheimer | 58 | 43 | 63 | Perform | - | 2024-09-14 |
| Piper Sandler | 55 | 30 | 86 | Overweight | 69 | 2024-11-18 |
| JP Morgan | 52 | 22 | 98 | Underweight | 33 | 2025-03-21 |
| B of A Securities | 48 | 21 | 78 | Underperform | 34 | 2025-02-12 |
| RBC Capital | 47 | 24 | 98 | Sector Perform | 40 | 2025-02-18 |
| Jefferies | 47 | 8 | 97 | Hold | 55 | 2024-10-15 |
Rows per page
1-10 of 14
Upgrades & Downgrades
| Maintains | JP Morgan: Underweight to Underweight | 3/21/2025 |
| Initiated | Citigroup: Neutral | 3/13/2025 |
| Maintains | UBS: Buy to Buy | 2/19/2025 |
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 2/18/2025 |
| Downgrade | Barclays: Overweight to Equal-Weight | 2/18/2025 |
| Maintains | B of A Securities: Underperform to Underperform | 2/11/2025 |
Related Tickers
NVAX Novavax, Inc.
7.00
-3.58%
BNTX BioNTech SE
94.95
-0.47%
CRSP CRISPR Therapeutics AG
36.99
-2.76%
VKTX Viking Therapeutics, Inc.
25.65
-1.84%
SAVA Cassava Sciences, Inc.
1.6500
-2.94%
REGN Regeneron Pharmaceuticals, Inc.
637.36
+0.24%
TNXP Tonix Pharmaceuticals Holding Corp.
20.17
-24.37%
VRTX Vertex Pharmaceuticals Incorporated
492.69
-1.96%
SLNO Soleno Therapeutics, Inc.
71.99
+6.83%
RXRX Recursion Pharmaceuticals, Inc.
5.81
-2.68%